Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfiz­er and their part­ners at the mR­NA spe­cial­ist BioN­Tech have pub­lished the first glimpse of bio­mark­er da­ta from an ear­ly-stage study spot­light­ing the “ro­bust im­muno­genic­i­ty” trig­gered by their Covid-19 vac­cine, which is one of the lead­ers in the race to van­quish the glob­al pan­dem­ic.

Re­searchers se­lect­ed 45 healthy vol­un­teers 18-55 years of age for the study. They were ran­dom­ized to re­ceive 2 dos­es, sep­a­rat­ed by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanopar­ti­cle-for­mu­lat­ed, nu­cle­o­side-mod­i­fied, mR­NA vac­cine that en­codes trimer­ized SARS-CoV-2 spike gly­co­pro­tein RBD.” Their re­spons­es were com­pared against the ef­fect of a nat­ur­al, pre­sum­ably pro­tec­tive de­fense of­fered by a reg­u­lar in­fec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.